Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Bispecific antibodies represent a significant advancement in non-small cell lung cancer (NSCLC) therapy.
• Recent approvals like amivantamab and zenocutuzumab demonstrate their efficacy in specific NSCLC subsets.
• These novel agents present unique on-target toxicities and implementation challenges.

Purpose of the Study:

• To review the evolving clinical data for bispecific antibodies in NSCLC, with a focus on amivantamab.
• To provide a practical framework for managing adverse events associated with bispecific antibody therapy.
• To explore quality-of-life, financial toxicity, and the impact of subcutaneous formulations.

Main Methods:

• Comprehensive review of clinical trial data for bispecific antibodies in NSCLC.
• Analysis of adverse event profiles, including dermatologic and infusion-related toxicities.
• Evaluation of patient-reported outcomes and emerging therapeutic strategies.

Main Results:

• Bispecific antibodies show promise in refractory NSCLC, including EGFR-mutant and HER2-altered disease.
• Management strategies for on-target toxicities are crucial for successful implementation.
• Emerging agents like ivonescimab may offer new frontline therapy options.

Conclusions:

• Bispecific antibodies are transforming NSCLC treatment, offering dual-pathway targeting.
• Effective management of toxicities and consideration of patient experience are vital.
• Further research and integration of real-world data will optimize their use in NSCLC care.